Rising healthcare costs and changing coverage increase financial burdens for individuals with hereditary conditions like ...

During the 2025 American Society of Hematology annual meeting, held earlier this month in Orlando, Florida, CURE sat down ...

Preoperative breast MRI did not improve LRR, DRFR, or OS outcomes in early-stage breast cancer patients. The trial involved ...

High-dose radiation with Keytruda led to increased infiltration of various immune cells and formation of tertiary lymphoid ...

The addition of the immune checkpoint inhibitor Tecentriq (atezolizumab) to neoadjuvant chemotherapy and as a single agent ...

Verzenio monotherapy provided clinical benefits to 33% of patients with HR-positive, HER2-negative breast cancer after prior ...

Tukysa (tucatinib) combined with Herceptin (trastuzumab) and Perjeta (pertuzumab) extended progression-free survival as a frontline maintenance approach compared with placebo plus Herceptin and ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...

Trodelvy did not show statistically significant PFS improvement over chemotherapy in hormone-receptor-positive/HER2-negative breast cancer post-endocrine therapy. Investigator-assessed PFS showed a ...

Emmy-winning journalist and author Suleika Jaouad recently delivered the keynote address at the inaugural Blood Cancer Heroes celebration. The event, held in partnership with Bloo ...

Silicone breast prostheses, once vital for balance and confidence, now symbolize survival and the complex interplay of joy and sorrow. After cancer, even your closet tells a story you never imagined ...

“In our real-world experience, [Yescarta] in relapsed or refractory follicular lymphoma showed durable responses and a ...